Skip to main content

Table 1 Patient and tumor characteristics

From: Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia

  Remission after Act-D treatment
(n = 96)
Resistant to Act-D treatment
(n = 39)
P
Median age (years) (range) at diagnosis 28.2 (17.9–53.7) 30.0 (18.2–51.6) 0.387
Median body weight (Kg) (range) 57 (40–88) 57 (44–91) 0.804
Median body height (cm) (range) 160.5 (150–170) 160 (150–170) 0.032
Median body mass index (kg/m2) (range) 21.8 (15.6–34.4) 21.9 (18.0–33.5) 0.561
Median parity (range) 2 (1–7) 2 (1–6) 0.180
Median gravidity (range) 0 (0–2) 1 (0–2) 0.086
Pathology of hydatid mole    0.425
 Partial mole 27/91 (29.7%) 14/38 (36.8%)  
 Complete mole 64/91 (70.3%) 24/38 (63.2%)  
Median numbers of curettage for hydatid mole (range) 2 (1–2) 2 (1–2) 0.665
Invasive uterine lesions    < 0.001
 No 85 (88.5%) 17 (43.6%)  
 Yes 11 (11.5%) 22 (56.4%)  
Median diameter of invasive uterine lesions (mm) (range) 21 (5–45)
(n = 11)
32.5 (13–87)
(n = 22)
0.026
FIGO staging    0.816
 Stage I 39 (40.6%) 15 (38.5%)  
 Stage III 57 (59.4%) 24 (61.5%)  
Median FIGO/WHO scores (range) 1 (0–6) 3 (0–6) < 0.001
Median serum β-hCG before chemotherapy (IU/L) (range) 339 (60–46,940) 5517 (86–159,160) < 0.001